ArticleLeukemia2024
High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia.
Abstract read
In one paragraph
Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013.Journal of hematology & oncology · 2026Trial
- Prognostic Impact of Sequential Measurable Residual Disease andAnnals of laboratory medicine · 2026Observational
- Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.Leukemia · 2026Article
- Article
- Incidence of Bloodstream Infections in Pediatric Patients with Cancer during Febrile Neutropenia: A Retrospective Study.JMA journal · 2025Article
- Article
- Adverse prognostic impact ofHaematologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Daisuke TomizawaDivision of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan. tomizawa-d@ncchd.go.jp.ORCID http://orcid.org/0000-0003-1520-7007
Jun MatsubayashiCenter for Clinical Research and Advanced Medicine, Shiga University of Medical Science, Otsu, Japan.ORCID http://orcid.org/0000-0003-4104-6833
Shotaro IwamotoDepartment of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.ORCID http://orcid.org/0000-0002-7710-2449
Hidefumi HiramatsuDepartment of Pediatrics, Graduate School of Medicine Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0003-3136-5670
Daisuke HasegawaDepartment of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9446-9568
Hiroshi MoritakeDivision of Pediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID http://orcid.org/0000-0001-5471-7646
Daiichiro HasegawaDepartment of Hematology and Oncology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
Kiminori TeruiDepartment of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID http://orcid.org/0000-0003-1294-8635
Asahito HamaDepartment of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital, Nagoya, Japan.ORCID http://orcid.org/0000-0002-7582-0201
Shin-Ichi TsujimotoDepartment of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID http://orcid.org/0000-0001-5738-4138
Nobutaka KiyokawaDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.ORCID http://orcid.org/0000-0001-9310-2126
Hayato MiyachiDepartment of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan.
Takao DeguchiDepartment of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.ORCID http://orcid.org/0000-0001-9932-4299
Yoshiko HashiiDepartment of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
Yuka Iijima-YamashitaClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.ORCID http://orcid.org/0000-0003-3954-258X
Tomohiko TakiDepartment of Medical Technology, Kyorin University Faculty of Health Sciences, Mitaka, Japan.ORCID http://orcid.org/0000-0002-0054-410X
Yasushi NoguchiDepartment of Pediatrics, Japanese Red Cross Narita Hospital, Narita, Japan.ORCID http://orcid.org/0000-0001-8349-5851
Kazutoshi KoikeDepartment of Pediatric Hematology/Oncology, Ibaraki Children's Hospital, Mito, Japan.
Katsuyoshi KohDepartment of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0002-0476-4978
Yuki YuzaDepartment of Hematology and Oncology, Tokyo Metropolitan Children's Medical Center, Fuchu, Japan.
Akiko Moriya SaitoClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.ORCID http://orcid.org/0000-0003-3723-8445
Keizo HoribeClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Takashi TagaDepartment of Pediatrics, Shiga University of Medical Science, Otsu, Japan.ORCID http://orcid.org/0000-0003-0525-4766
Shiro TanakaDepartment of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0001-6817-5235
Souichi AdachiHuman Health Science, Kyoto University, Kyoto, Japan.
Funding
Japan Agency for Medical Research and Development (AMED) JP17ck0106329Japan Agency for Medical Research and Development (AMED) JP20ck0106604Ministry of Health, Labour and Welfare (Ministry of Health, Labour and Welfare, Japan) H23-Gan Rinsho-Ippan-014Ministry of Health, Labour and Welfare (Ministry of Health, Labour and Welfare, Japan) H26-Kakushinteki Gan-Ippan-061National Center for Child Health and Development (NCCHD) 22-5National Center for Child Health and Development (NCCHD) 26-20
Abstract
PubMed holds no abstract for this paper.
Indexed as
CytarabineLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsChildHumansInduction ChemotherapyNeoplasm, ResidualRemission InductionCytarabine
Identifiers
PMID
37926712What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.